Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 175 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lyrica Clear all
Completed Not applicable Interventional Results available

Pregabalin in CIPN

NCT02394951
View directory record Official record
Conditions
Neuropathy, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

NCT00437281
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
21 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Gralise to Treat Fibromyalgia Patients

NCT02052414
View directory record Official record
Conditions
Fibromyalgia
Interventions
Gabapentin ER
Drug
Lead sponsor
The Center for Clinical Research, Winston-Salem, NC
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

NCT02701764
View directory record Official record
Conditions
Dry Eye
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Pre vs Post Block in Total Knee Arthroplasty (TKA)

NCT05974501
View directory record Official record
Conditions
Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain
Interventions
Dexamethasone, Acetaminophen, Lyrica, Celebrex, Meloxicam, Oxycodone, Ropivacaine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00371033
View directory record Official record
Conditions
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Male only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

A Controlled Pregabalin Trial In Fibromyalgia

NCT00230776
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
89
States / cities
Little Rock, Arkansas • Fresno, California • La Jolla, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01257529
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388
View directory record Official record
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 9, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional Results available

Preemptive Analgesia Following Uterine Artery Embolization

NCT01555073
View directory record Official record
Conditions
Uterine Fibroids, Uterine Artery Embolization
Interventions
pregabalin/celecoxib, pregabalin/placebo, celecoxib/placebo, Placebo group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Pregabalin vs. Gabapentin on Reducing Opioid Usage

NCT04705480
View directory record Official record
Conditions
Analgesics, Gabapentin, Injuries, Narcotics, Pain, Trauma
Interventions
Pregabalin 50mg, Gabapentin 300mg, Neither Pregabalin nor Gabapentin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 9, 2026, 2:08 PM EDT
Withdrawn Phase 4 Interventional

Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline

NCT01309074
View directory record Official record
Conditions
Epilepsy, Anxiety
Interventions
Pregabalin-Lyrica, Sertraline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo

NCT00631696
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
13
States / cities
Mobile, Alabama • Phoenix, Arizona • Tarzana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159679
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

NCT02607254
View directory record Official record
Conditions
Idiopathic Small Fiber Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 4 Interventional

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159731
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Pregabalin as Treatment for Alcohol Use Disorder

NCT03256253
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Pregabalin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

NCT00151528
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 9, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional

Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study

NCT02202369
View directory record Official record
Conditions
Single Level Lumbar Decompression and Fusion Spine Surgery
Interventions
Multimodal Analgesia Treatment, Standard of Care Pain Management Protocol
Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

NCT00413010
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
35
States / cities
Arcadia, California • Burbank, California • Redlands, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 9, 2026, 2:08 PM EDT